Zoledronic Acid Approved in Canada for Postmenopausal Osteoporosis

Lila de Tantillo Health Guide
  • Zoledronic acid, a once-yearly infusion, has been approved by Health Canada for treatment of postmenopausal osteoporosis. Known as Reclast in the U.S., the bisphosphonate medication received FDA approval for that purpose just a few months ago. It will be sold as Aclasta in Canada and will help provide osteoporosis patients in the country one more option for strengthening their bones.
    Add This Infographic to Your Website or Blog With This Code:
Published On: November 11, 2007